Related Experiment Video
Updated: Aug 8, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Treatment of non-alcoholic fatty liver disease
1School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Perth, Australia.
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is common and may progress to cirrhosis and its complications. The pathogenesis of steatosis and cellular injury is thought to be related mostly to insulin resistance and oxidative stress. Therefore, management entails identification and treatment of metabolic risk factors, improving insulin sensitivity, and increasing antioxidant defences in the liver. Weight loss and exercise improve insulin sensitivity. Bariatric surgery may improve liver histology in patients with morbid obesity. Insulin sensitising drugs showed promise in pilot trials as have a number of hepatoprotective agents. Further randomised, well controlled trials are required to determine the efficacy of these drugs.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Atherosclerosis III: Management
Cirrhosis I: Introduction
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Alzheimer's Disease: Treatment

